German pharmaceutical group Stada, which is owned by Bain Capital and Cinven, is reportedly in discussions with two private equity firms regarding a potential sale of the company, according to a report by Reuters.
The firm’s owners are said to be evaluating strategic options and may pursue an initial public offering (IPO) in October should sale negotiations not advance, the newspaper reported, citing an unnamed source.
A spokesperson for Stada confirmed to Reuters that the company is actively assessing various ownership scenarios in collaboration with its shareholders, including both a potential sale and a public listing.
The news follows a report from March in which Reuters noted that Stada had postponed a planned Frankfurt IPO due to heightened market volatility.
On the operational front, Stada on Tuesday reported a 5% year-on-year increase in first-quarter operating EBITDA before special items, reaching €245m on a currency-adjusted basis, buoyed by robust sales of specialty pharmaceuticals.
